Benjamin Looker is General Counsel of Esperion Therapeutics, Inc.. Currently has a direct ownership of 183,663 shares of ESPR, which is worth approximately $442,627. The most recent transaction as insider was on Mar 14, 2024, when has been sold 100,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 184K
0% 3M change
119.53% 12M change
Total Value Held $442,627

Benjamin Looker Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 14 2024
BUY
Grant, award, or other acquisition
-
100,000 Added 35.25%
183,663 Common Stock
Apr 19 2023
SELL
Open market or private sale
$1,638 $1.27 p/Share
1,290 Reduced 1.52%
83,663 Common Stock
Mar 14 2023
BUY
Grant, award, or other acquisition
-
20,500 Added 19.44%
84,953 Common Stock
Jan 18 2023
SELL
Open market or private sale
$44,429 $7.0 p/Share
6,347 Reduced 8.96%
64,453 Common Stock
Jan 27 2022
BUY
Grant, award, or other acquisition
-
70,800 Added 50.0%
70,800 Common Stock
BL

Benjamin Looker

General Counsel
Ann Arbor, MI

Track Institutional and Insider Activities on ESPR

Follow Esperion Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR